MX9304435A - Compuesto y composicion farmaceutica para el tratamiento y la profilaxis de la obesidad o para el tratamiento de la diabetes del tipo ii. - Google Patents
Compuesto y composicion farmaceutica para el tratamiento y la profilaxis de la obesidad o para el tratamiento de la diabetes del tipo ii.Info
- Publication number
- MX9304435A MX9304435A MX9304435A MX9304435A MX9304435A MX 9304435 A MX9304435 A MX 9304435A MX 9304435 A MX9304435 A MX 9304435A MX 9304435 A MX9304435 A MX 9304435A MX 9304435 A MX9304435 A MX 9304435A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- prophylaxis
- composition
- obesity
- diabetes
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 5
- 238000011321 prophylaxis Methods 0.000 title abstract 3
- 208000008589 Obesity Diseases 0.000 title abstract 2
- 235000020824 obesity Nutrition 0.000 title abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 229940075420 xanthine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929215633A GB9215633D0 (en) | 1992-07-23 | 1992-07-23 | Novel treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9304435A true MX9304435A (es) | 1994-04-29 |
Family
ID=10719151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9304435A MX9304435A (es) | 1992-07-23 | 1993-07-22 | Compuesto y composicion farmaceutica para el tratamiento y la profilaxis de la obesidad o para el tratamiento de la diabetes del tipo ii. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0651642A1 (h) |
| JP (1) | JPH07509456A (h) |
| CN (1) | CN1043610C (h) |
| AU (1) | AU4714393A (h) |
| GB (1) | GB9215633D0 (h) |
| MX (1) | MX9304435A (h) |
| TW (1) | TW258663B (h) |
| WO (1) | WO1994002150A1 (h) |
| ZA (1) | ZA935339B (h) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5783408A (en) * | 1995-06-07 | 1998-07-21 | Hamilton; Bradford S. | Method for screening potential anti-obesity agents |
| RS55023B1 (sr) * | 2001-02-24 | 2016-11-30 | Boehringer Ingelheim Pharma | Derivati ksantina, njihovo dobijanje i njihova primena kao lekova |
| US6869947B2 (en) | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| EP1404675B1 (en) * | 2001-07-03 | 2008-03-12 | Novo Nordisk A/S | Dpp-iv-inhibiting purine derivatives for the treatment of diabetes |
| EP1463727A2 (en) * | 2001-09-19 | 2004-10-06 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| DE10254304A1 (de) * | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
| US7776893B2 (en) | 2003-09-05 | 2010-08-17 | Nycomed Gmbh | Use of PDE4 inhibitors for the treatment of diabetes mellitus |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004030502A1 (de) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| AU2006222060B2 (en) | 2005-03-08 | 2011-09-01 | Takeda Gmbh | Roflumilast for the treatment of diabetes mellitus |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| BRPI0711558A2 (pt) | 2006-05-04 | 2011-11-08 | Boeringer Ingelheim Internat Gmbh | polimorfos |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| EP2344195A2 (en) | 2008-09-10 | 2011-07-20 | Boehringer Ingelheim International GmbH | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| NZ592924A (en) | 2008-12-23 | 2014-05-30 | Boehringer Ingelheim Int | Salt forms of a xanthine derivative |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| US9186392B2 (en) | 2010-05-05 | 2015-11-17 | Boehringer Ingelheim International Gmbh | Combination therapy |
| EP3725325B1 (en) | 2010-06-24 | 2023-05-31 | Boehringer Ingelheim International GmbH | Diabetes therapy |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| CN103781788B (zh) | 2011-07-15 | 2016-08-17 | 勃林格殷格翰国际有限公司 | 经取代的喹唑啉、其制备及其在药物组合物中的用途 |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| ES2929025T3 (es) | 2012-05-14 | 2022-11-24 | Boehringer Ingelheim Int | Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia |
| EP2849755A1 (en) | 2012-05-14 | 2015-03-25 | Boehringer Ingelheim International GmbH | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｄｐｐ−４阻害薬の医学的使用 |
| KR102391564B1 (ko) | 2016-06-10 | 2022-04-29 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴 및 메트포르민의 병용물 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8906792D0 (en) * | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
-
1992
- 1992-07-23 GB GB929215633A patent/GB9215633D0/en active Pending
-
1993
- 1993-07-21 EP EP93917883A patent/EP0651642A1/en not_active Withdrawn
- 1993-07-21 WO PCT/GB1993/001539 patent/WO1994002150A1/en not_active Application Discontinuation
- 1993-07-21 JP JP6504294A patent/JPH07509456A/ja active Pending
- 1993-07-21 AU AU47143/93A patent/AU4714393A/en not_active Abandoned
- 1993-07-22 MX MX9304435A patent/MX9304435A/es unknown
- 1993-07-22 CN CN93116874A patent/CN1043610C/zh not_active Expired - Lifetime
- 1993-07-23 ZA ZA935339A patent/ZA935339B/xx unknown
- 1993-07-27 TW TW082105967A patent/TW258663B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TW258663B (h) | 1995-10-01 |
| GB9215633D0 (en) | 1992-09-09 |
| ZA935339B (en) | 1995-01-18 |
| WO1994002150A1 (en) | 1994-02-03 |
| CN1114880A (zh) | 1996-01-17 |
| CN1043610C (zh) | 1999-06-16 |
| EP0651642A1 (en) | 1995-05-10 |
| AU4714393A (en) | 1994-02-14 |
| JPH07509456A (ja) | 1995-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9304435A (es) | Compuesto y composicion farmaceutica para el tratamiento y la profilaxis de la obesidad o para el tratamiento de la diabetes del tipo ii. | |
| DE3587434D1 (de) | Antivirale pharmazeutische zusammensetzungen und ihrer verwendung. | |
| BR9106977A (pt) | Metodo para suprimir destruicao autoimune de celuias beta pancreaticas,formulacao farmaceutica,metodo de profilaxia,metodo para prevenir o surgimento de diabetes tipo 1 e metodo para tratar um mamifero | |
| ES2128552T3 (es) | Combinacion de un inhibidor de la biosintesis del colesterol y un inhibidor de la absorcion del colesterol beta-lactama. | |
| KR950002785A (ko) | 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜 | |
| ZA921538B (en) | Therapeutic compositions to protect and resuscitate mammalian cells and methods for preparing and using same | |
| ES2182837T3 (es) | Piran-2-onas y 5,6-dihidropiran-2-onas utiles en el tratamiento del sida y de otros retrovirus. | |
| CA2002859A1 (en) | Method of treating epithelial disorders | |
| PE13197A1 (es) | Venlafaxina en el tratamiento de amenorrea hipotalamica en mujeres no deprimidas | |
| NO940266L (no) | Indre strålingsskade | |
| MY106067A (en) | Benzisothiazolinone-1-dioxide derivatives as elastase inhibitors. | |
| NO900251L (no) | Fremgangsmaate for behandling eller hindring av intrinsik aldret hud med retinoider. | |
| AR247984A1 (es) | Metodo para la preparacion de una composicion sinergica que tiene actividad antiplaca o antigingivitis | |
| MX9301387A (es) | Metodo y composicion para el tratamiento de osteoporosis. | |
| IL100874A0 (en) | Oxypurine nucleosides and their congeners,and acyl derivatives thereof,for improvement of hematopoiesis | |
| SE8904354D0 (sv) | A pharmaceutical composition | |
| FI951511A0 (fi) | IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon | |
| CO4130200A1 (es) | Inhibidores de proteasa del hiv utiles en el tratamiento del sida | |
| MD960168A (ro) | Metodă şi compuşi pentru tratamentul infecţiilor virale | |
| PE2591A1 (es) | Composicion y metodo para reducir la afliccion gastrointestinal debido a azucares que contienen alfa-d-galactosidos | |
| SE0004101D0 (sv) | New use | |
| MX173156B (es) | Composiciones para tratar o evitar la placa dental o enfermedades gingivales o periodontales de la cavidad oral en humanos o animales inferiores | |
| MX9400040A (es) | Composiciones para tratar trastornos respiratorios. | |
| MX9302985A (es) | Composicion farmaceutica para el tratamiento y la profilaxis de la ansiedad. | |
| BR9810292A (pt) | Tratamento de diabete com tiazolidinadiona, secretagogo de insulina e inibidor de alfa-glicosidase |